This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

42/100

✓ Peer-reviewed alzhub usefulness score 42 out of 100. TREM2 and immune genetics

Topic: Brain proteins, microglia and lab models

Background and purpose Neuroinflammation plays a role in the aetiopathogenesis of Alzheimer's disease (AD). Triggering receptor expressed on myeloid cells 2 (TREM2), a cell surface receptor of the immunoglobulin superfamily, seems to have protective anti-inflammatory activity in AD. Methods Triggering receptor expressed on myeloid cells 2 expression was analysed in peripheral blood mononuclear cells from healthy subjects (CT) and from patients with either AD or mild cognitive impairment (MCI).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Casati, M., Ferri, E., Gussago, C., Mazzola, P., Abbate, C., Bellelli, G., et al. (2018). Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease. European journal of neurology. https://doi.org/10.1111/ene.13583

Vancouver

Casati M, Ferri E, Gussago C, Mazzola P, Abbate C, Bellelli G, et al. Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease. European journal of neurology. 2018. doi:10.1111/ene.13583. PMID: 29377401.

BibTeX

@article{casati2018-29377401,
  author  = {Casati, M. and Ferri, E. and Gussago, C. and Mazzola, P. and Abbate, C. and Bellelli, G. and Mari, D. and Cesari, M. and others},
  title   = {{Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease}},
  journal = {European journal of neurology},
  year    = {2018},
  doi     = {10.1111/ene.13583},
  pmid    = {29377401},
  url     = {https://doi.org/10.1111/ene.13583}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Triggering receptor expressed on myeloid cells 2 (TREM2), a cell surface receptor of the immunoglobulin superfamily, seems to have protective anti-inflammatory activity in AD.
Methods Triggering receptor expressed on myeloid cells 2 expression was analysed in peripheral blood mononuclear cells from healthy subjects (CT) and from patients with either AD or mild cognitive impairment (MCI).
MCI patients were re-evaluated at a 2-year follow-up to investigate their progression to AD (MCI-AD) or lack thereof (MCI-MCI).
Results Triggering receptor expressed on myeloid cells 2 gene expression was higher in AD than CT patients, but was highest in MCI.

Why it matters

This study found increased TREM2 expression in peripheral cells from mild cognitive impairment patients who progressed to Alzheimer's disease. It is an observational biomarker study and does not report a treatment or cure.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Evidence strengthLow

How this study scored 42/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (European journal of neurology)
Journal's citation record	2 / 4	European Journal of Neurology: journal h-index 181 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2018 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	4 / 7	Cited 66 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	6.6 citations a year over 10 year(s) since 2018
Impact for its field and year	3 / 6	Cited 3.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	2 / 6	Cited by 8 other studies in this library
Still being cited	2 / 4	Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Beatrice Arosio: h-index 48 (OpenAlex, whole career)
Institution's track record	1 / 3	University of Milan: institution h-index 1,023 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 29377401)
Free to read	0 / 2	Behind a paywall — scores zero
Total	42 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in TREM2 and immune genetics

Also tagged “macrophages”

363 studies in the library carry the topic tag “macrophages”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →